Evidence map›Paper›PMID 41492112›Full record

ArticleAnnals of surgical oncology2026

From Proteomics to Pathology: S100A8's Impact on Breast Phyllodes Tumors Grading.

Yan Shao, Xiaoyang Wang, Jiali Yang, Yi Huang, Lili Qian, Yu Xie, Meihua Ye, Juan Liu, Yanling Jin

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yan Shao *Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Xiaoyang Wang *Biomedical Analysis Center, Army Medical University, Chongqing, China.
Jiali YangThe Second School of Clinical Medicine of Zhejiang, Chinese Medical University, Hangzhou, China.
Yi HuangBiomedical Analysis Center, Army Medical University, Chongqing, China.
Lili QianCancer Center, Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China.
Yu XieCenter for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Meihua YeCancer Center, Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China.
Juan Liu *Department of General Medicine, Daping Hospital, Army Medical University, Chongqing, China. liujuan961@tmmu.edu.cn.
Yanling Jin *Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China. jinyl91@163.com.

Funding

Basic Public Welfare Research Program of Zhejiang Province LGF21H160031Chongqing Natural Science Foundation CSTB2022NSCQ-MSX0163Medical Health Science and Technology Project of Zhejiang Provincial Health Commission 2022PY039
6 · The paper itself

Abstract

backgroundBreast phyllodes tumors (PT) are classified as benign, borderline, or malignant, primarily based on histological features, but lack reliable biomarkers for grading. Our aim is to find a protein marker to improve the accuracy of PT grading.

methodsWe analyzed formalin-fixed paraffin-embedded (FFPE) samples of fibroadenoma (FA) and PT using quantitative proteomics to screen the protein marker S100A8, confirmed its role in PT grading via immunohistochemistry, and examined its correlation with clinicopathological features.

resultsQuantitative proteomics studies showed that the differential proteins between FA and PT primarily involve calcium ion binding, including S100A8, FKBP10, MMP9, SPARC, and MMP14. Meanwhile, the proteomic studies showed a statistically significant increase in the expression of S100A8 in malignant PT compared with benign PT. Immunohistochemical validation showed that S100A8 was predominantly expressed in the nucleus and cytoplasm of stromal cells in malignant PT. The expression level of S100A8 in stromal cells demonstrated a positive correlation with PT categories (p < .001), as well as with Ki67 expression (p < .001).

conclusionsTo the best of our knowledge, this study is the first to demonstrate the integration of S100A8 and Ki67 expression in stromal cells with histological characteristics aids in grading PT.

Indexed as

Biomarkers, TumorBreast NeoplasmsCalgranulin AFibroadenomaPhyllodes TumorProteomicsAdultFemaleFollow-Up StudiesHumansKi-67 AntigenMiddle AgedNeoplasm GradingPrognosisStromal CellsBiomarkers, TumorCalgranulin AKi-67 AntigenS100A8 protein, humanBreast fibroepithelial lesionsFibroadenomaPhyllodes tumorProteomicS100A8

Identifiers

PMID41492112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.